Retina Update 2026 - Featuring the 2nd Joseph I. Maguire, MD Memorial Lecture

Originally Presented: Saturday, April 18, 2026

Wills Eye Auditorium

Conference Description:
The 2nd Joseph I. Maguire, MD Memorial Lecture will be delivered by Jayanth Sridhar, MD, Chief of Ophthalmology at Olive View UCLA Medical Center in California.

With the emergence of new technologies, treatments, and clinical trial results, ophthalmologists need to understand how to incorporate these advances into clinical care. We will discuss latest advances in the management of inherited and acquired ophthalmic diseases and evidence for emerging therapies and screening modalities. Both didactic and case-based educational formats will be utilized to illustrate current trends in the management of complex and routine ophthalmic patients, taking into account diagnostics as well as nonsurgical and surgical treatment.

At the conclusion of the course, participants should be able to:
1 Determine if Tap/Inject or early PPV is a better technique for endophthalmitis
2 Review masquerade symptoms of uveitis
3 Evaluate pediatric retinal detachments
4 Determine if Home OCT is a viable option for the current state of practice
5 Develop a strategy to classify the severity and treatment of diabetic retinopathy

Accreditation Statement:
The Wills Eye Hospital is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Statement Designation:
Wills Eye Hospital designates this Live Activity for a maximum of 3.50 *AMA PRA Category 1 Credits*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Statement:
It is the policy of Wills Eye Hospital that the information presented at Wills Eye Hospital's CME activities will be commercially unbiased and based on scientific and clinical evidence. To help participants make judgments about the presence of commercial bias, Wills Eye Hospital provides information that planners and speakers have disclosed about financial relationships they have with commercial entities that produce, market, re-sell, or distribute health care goods or services consumed by, or used on, patients. All relevant financial relationships have been mitigated.

Name of individual	Individual's role in activity	Nature of Relationship(s) / Name of Ineligible Company(s)
Nikhil Bommakanti, MD	Faculty	Consulting Fee-REGENXBIO, Inc. (Relationship has ended)|Consulting Fee-EyePoint Pharmaceuticals

		(Relationship has ended)|Consulting Fee-Alimera Sciences (Relationship has ended)
Michael N Cohen, MD	Faculty, Planner	Nothing to disclose
Daniel Connors, MD	Faculty	Nothing to disclose
James P. Dunn, MD	Faculty	Nothing to disclose
David Fell, MD	Faculty	Consulting Fee-Bausch + Lomb
Mitchell Fineman, MD	Faculty	Nothing to disclose
Margaret Greven, MD	Faculty	Nothing to disclose
Jason Hsu, MD	Faculty	Consulting Fee-Astellas (Relationship has ended)|Consulting Fee-Gyroscope Therapeutics (Relationship has ended)|Grant or research support-Genentech|Grant or research support-Astellas Pharma|Grant or research support-Stealth Biotherapeutics|Consulting Fee-Nextech|Grant or research support-Regeneron|Grant or research support-Boehringer Ingelheim|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Neurotech|Consulting Fee-RetinAI
Thomas Jenkins, MD	Faculty	Speakers Bureau-Regeneron
Richard S. Kaiser, MD	Faculty	Nothing to disclose
Ajay E. Kuriyan, MD	Faculty, Planner	Stocks or stock options, excluding diversified mutual funds-Recens medical|Stocks or stock options, excluding diversified mutual funds-Lumata Health|Stocks or stock options, excluding diversified mutual funds-Co-Sign AI|Grant or research support-4DMT|Speakers Bureau-Genentech|Consulting Fee-Alimera Sciences|Grant or research support-Alcon|Grant or research support-Aderum Biotechnologies, Inc.|Consulting Fee-Allergan|Consulting Fee-Bausch + Lomb|Consulting Fee-EyePoint Pharmaceuticals|Grant or research support-EyePoint Pharmaceuticals|Consulting Fee-Genentech|Grant or research support-Genentech|Consulting Fee-LifeNet Health|Consulting Fee-Novartis|Consulting Fee-Optos, Inc.|Grant or research support-Annexon

Erik M Massenzio, MD	Peer Reviewer	Nothing to disclose
Justin Muste, MD	Peer Reviewer	Nothing to disclose
Anton Orlin, MD	Faculty	Membership on Advisory Committees or Review Panels, Board Membership, etc.-Allergan (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Zeiss (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Genentech (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Apellis Pharmaceuticals (Relationship has ended)
Samir N Patel, MD	Faculty	Membership on Advisory Committees or Review Panels, Board Membership, etc.-Regeneron (Relationship has ended)|Consulting Fee-Bausch + Lomb (Relationship has ended)
Jose Pulido, MD, MS, MPH, MBA	Faculty	Nothing to disclose
Carl D. Regillo, MD	Faculty	Consulting Fee-Allergan|Consulting Fee-Apellis Pharmaceuticals|Consulting Fee-EyePoint Pharmaceuticals|Consulting Fee-Genentech|Consulting Fee-Novartis|Consulting Fee-Ocugen|Consulting Fee-REGENXBIO, Inc.|Consulting Fee-Regeneron|Consulting Fee-Astellas Pharma|Consulting Fee-Ocular Therapeutix|Consulting Fee-Zeiss (Relationship has ended)|Consulting Fee-Aderum Biotechnologies, Inc.|Consulting Fee-Alcon|Consulting Fee-Bausch + Lomb|Consulting Fee-Boehringer Ingelheim
Collin Richards, MD	Peer Reviewer	Nothing to disclose
Linnet Rodriguez, MD	Faculty	Consulting Fee-AbbVie
Chirag Shah, MD	Faculty	Grant or research support-Aviceda (Relationship has ended)|Grant or research support-EyePoint Pharmaceuticals
Arunan Sivalingam, MD	Faculty	Nothing to disclose

Jay Sridhar, MD	Faculty	Consulting Fee-Alcon|Consulting Fee-AbbVie|Consulting Fee-EyePoint Pharmaceuticals|Consulting Fee-Genentech|Consulting Fee-Regeneron|Consulting Fee-Samsara|Consulting Fee-4DMT
Joshua H Uhr, MD	Faculty	Public Corp Stock-Apellis Pharmaceuticals|Consulting Fee-Bausch + Lomb
Duo Xu, MD	Faculty	Consulting Fee-Gyroscope Therapeutics|Advisor-Apellis|Consulting Fee-Bausch + Lomb|Consulting Fee-Zeiss|Consulting Fee-REGENXBIO, Inc.|Consulting Fee-Alimera Sciences (Relationship has ended
Timothy T Xu, MD	Peer Reviewer	Nothing to disclose
Yoshihiro Yonekawa, MD	Faculty	Consulting Fee-Alcon (Relationship has ended)|Consulting Fee-Bausch + Lomb (Relationship has ended)|Consulting Fee-Apellis Pharmaceuticals (Relationship has ended)|Consulting Fee-Genentech|Grant or research support-Genentech|Grant or research support-Regeneron|Grant or research support-Ocugen|Grant or research support-Kyowa Kirin|Grant or research support-Eyebiotech